Neurizon Presents Company Update and 2025 Outlook
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Neurizon Presents Company Update and 2025 Outlook
12 December 2024 – Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or
“the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is
pleased to announce a presentation by Dr. Michael Thurn, the Company’s Managing Director and CEO, to update
the shareholders about the Company’s latest developments and 2025 Outlook.
The presentation, titled "Shaping the Future of Neurodegenerative Diseases: Neurizon’s Mid-Year Update &
Outlook" outlines the following:
The Company’s strategy and a clear focus on transforming the horizon of neurodegenerative disease
treatments and bringing NUZ-001 to market for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Deep dive into the latest positive preclinical results for NUZ-001, demonstrating the effectiveness in
reducing the aggregation of TDP-43, a key pathological feature of ALS.
Company’s regulatory success and future milestones.
Preparation and key activities for the participation in Phase 2/3 HEALEY ALS Platform Trial.
Presentation slides are available as an attachment to this announcement. The recording of the presentation will
be made available on Neurizon’s website at www.neurizon.com.
-ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:
Dr. Michael Thurn
Managing Director and Chief Execufive Officer
Neurizon Therapeufics Limited
enquiries@neurizon.com
+61 (3) 9692 7222
Catherine Strong
Sodali & Co
catherine.strong@sodali.com
+61 (0)406 759 268
Level 4, 96-100 Albert Road, South Melbourne, VIC 3205 Tel: +61 3 9692 7222
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to
accelerate access to effective ALS treatments for patients while exploring NUZ-001’s potential for broader
neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders.
Neurizon Investor Hub
We encourage you to ufilise our Investor Hub for any enquiries regarding
announcement or other aspects concerning Neurizon.
This plafform offers an opportunity to submit quesfions, share comments,
and view video summaries of key announcements.
this
To access Neurizon Investor Hub please scan the QR code or visit
hftps://investorhub.neurizon.com
Level 4, 96-100 Albert Road, South Melbourne, VIC 3205 Tel: +61 3 9692 7222
Shaping the future of
neurodegenerative diseases
Neurizon’s Mid-Year Update & Outlook
12 December 2024
ASX: NUZ
Disclaimer
Thi s disclaimer applies to this presentation and the information cont ained in it
(This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”). It does not
purport to contai n all the i nformation that a prospective investor may require in connection with any potential
investment in the Company. You should not treat the contents of this presentation, or any i nformation provided
in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or
investment matters.
No representation or warranty (whet her express or implied) i s made by the Company or
any of its officers, advi sers, agents or employ ees as to t he accuracy , compl eteness or reasonableness of the
informati on, statements, opinions or matters (express or implied) arising out of, contained in or derived from
this presentation or provided in connection with i t, or any omissi on from t hi s present ation, nor as t o the
attai nability of any estimates, forecasts or projections set out i n this presentation.
Thi s present ation i s provided expressly on the basis that y ou wil l carry out your own independent inquiri es into
the matters contained in t he presentation and make your own independent decisions about the affai rs, financial
position or prospects of the Company .
The Company reserves the right t o update, amend or supplement t he informat ion at any time in its absolute
discretion (without incurri ng any obl igation to do so).
Neither the Company, nor its relat ed bodies corporate, officers, their advisers, agents and empl oyees accept any
responsibili ty or liabil ity to you or to any other person or entity arisi ng out of this presentation including
pursuant to the general law (whether for negligence, under statute or otherwi se), or under t he Australian
Securit ies and Investment s Commi ssion Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or
any corresponding provision of any Australian state or territory legislat ion (or the law of any simi lar legislat ion in
any other jurisdiction), or simi lar provision under any applicable law. Any such responsibili ty or liabil ity is, to the
maximum extent permit ted by law, expressly discl aimed and excl uded.
Nothing in this material should be construed as either an offer to sell or a soli citat ion of an offer to buy or sell
securities. It does not include all available information and should not be used in isolation as a basis to invest in
the Company.
Future Matters
Thi s present ation contains reference to certain intentions, expectations, future plans, strategy and
prospect s of t he Company. Those i nt entions, expectations, future plans, strategy and prospects may or may
not be achieved. They are based on certain assumptions, which may not be met or on whi ch views may
differ and may be affected by known and unknown risks. The performance and operat ions
of the Company may be influenced by a number of fact ors, many of which are out side the control of the
Company. No representati on or warranty , express or implied, i s made by the Company, or any of its
directors, offi cers, employees, advisers or agents that any intentions, expectations or plans wil l be achieved
either totally or partially or that any particular rate of return will be achieved.
Given the risks and uncertainties t hat may cause t he Company’s actual future results, performance or
achi evements to be materially di fferent from those expected, planned or intended, recipients should not
place undue reliance on these intentions, expect ations, future plans, strategy and prospects. The Company
does not warrant
or represent that the actual resul ts, performance or achi evements will be as expected, planned or
intended.
US Disclosure
Thi s document does not const itute any part of any offer to sell, or the sol icitation of an offer to buy, any
securities in the Uni ted Stat es or to, or for the account or benefit of any “US person” as defined in
Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company ’s shares have not been,
and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of
the United States, and may not be offered or sold in the United States or to any US person without bei ng so
regi stered or pursuant to an exempti on from registration including an exempt ion for quali fi ed instituti onal
buyers.
Mid-Year Update & Outlook December 2024
2
Mid-Year Update & Outlook December 2024
3
Investment credentials for NUZ-001
Orally Bioavailable
Strong IP Position
Ease of delivery
Patent protection beyond 2040
Crosses blood brain barrier
Near-term regulatory strategy
Centrally acting drug
Accelerated approval possible across multiple
jurisdictions
Solid scientific foundation
Additional indications
Reduces TDP-43 accumulation
Pipeline synergies to leverage commercial
infrastructure across development programs
Long-term safety data
Experienced Management
Animal and human safety database
accumulating
Experienced world-class Board, SAB and
management team
Positive Phase 1 efficacy data
High deal flow
Animal Efficacy signals
Neurology assets in demand with 4 ALS deals over
the last year alone
Mid-Year Update & Outlook December 2024
4
Pipeline
Multiple synergistic product opportunities in neurodegenerative disease
• Single pivotal registration
clinical study for ALS
• Targeting accelerated approval
from Phase 2 data
• Access to HEALEY ALS Platform
Trial reduces study cost and
time, and increases patient
participation rate
HREC – Human Research Ethics Committee; IND – Investigational New Drug; IRB – Institutional Review Board.
Mid-Year Update & Outlook December 2024
5
2024 - A Year of Milestones at Neurizon
• Positive Phase 1
MEND Study Results
• FDA Pre-IND Meeting
• Start of the Extension
Study
• Formed Scientific
Advisory Board
• Final Ethics
approval for OLE
• Head of
Manufacturing
appointment
• OLE Study Survival
Data
• Phase 1 Study Data
Presentation at
ENCALS
• Raised $10 mil
• Appointment of Dr.
Katie MacFarlane
• Positive Interim
Study Results OLE
• Annual Report
• Presentation at
MND Australia
Symposium
April
June
August
February
• Neurizon Brand
Launch
• AGM
• Presentation at NEALS
Meeting
• Tax Incentive Rebate
• First patient 2 years
on NUZ-001
• Additional Tax Incentive
Rebate
• Company Update
Webinar
• Expected OMPD
Designation
• Participation at
International
Symposium on ALS
October
December
January
March
May
July
September
November
• FDA Feedback for
ODD Approval
• FDA Granted PreIND Meeting
• Ethics Committee
Approval for OLE
• Partnered with Berry
Consultants
• Positive Clinical
Data filed for ODD
• Presentation at
Singapore Health
Day
• Presentation at
NWR Virtual
Healthcare
conference
• ODD by FDA
• Appointment of MD
& CEO Michael Thurn
and CSO
• Appointment of
Company Secretary
• Change of the Office
Location
• Appointment of
Chair Sergio Duchini
• Appointment of
Marcus Hughes
• Selection into HEALEY
ALS Platform Trial
• Granted SME status
by EMA
• Completed Share
Purchase Plan $7.9
mil
• EMA PreSubmission Meeting
• Appointment of
Head of Marketing
& Corporate Affairs
• Partnering and
Presentation at the
Boston Conference
• Positive
Preclinical Data
• Positive Opinion
on OMPD
• Entered
Partnership with
GenieUs
• Presentation at
ALS ONE
• Presentation at
AusBio Invest
ALS – Amyotrophic Lateral Sclerosis; EMA – European Medicines Agency; HREC – Human Research Ethics Committee; IND – Investigational New Drug; ODD – Orphan Drug
Designation; FDA - Food and Drug Administration, OMPD – Orphan Medicinal Product Designation ; OLE – Open Label Extension; SME – Small and Medium Enterprise.
Mid-Year Update & Outlook December 2024
6
Meet Our
Board of Directors
Sergio Duchini
Chairman & Non-Executive Director
Dr Michael Thurn
Managing Director & Chief Executive
Dr Katie MacFarlane
Non-Executive Director
Marcus Hughes
Non-Executive Director
Sergio serves as a N on-Executive Director
and Chair of the Audit Committee at Enlitic Inc.
Additionally, he holds the position of Chair at
Lymphoma Australia, a leading not-for-profit
organization. Sergio previous ly sat on the
AusBiotech Board of Directors for nine years.
He also served as a Board Director at Deloitte
Australia, overs eeing the governance,
strategy development, and stewardship
of the partnership.
Michael has over 25 years experience in technical,
regulatory, commercial and management roles in
research organisations and indus try, including
early stage, fast growing, private and publicly
listed biotechnology companies . Michael has led a
variety of US IND applications across a range of
therapeutic areas and evaluated drugs and
vaccines for registration during his engagement at
the TGA.
Katie has over 30 years of experience in th e
development and commercialisation of
pharmaceutical products and devices. She has
held senior executive pos itions at Arkayli
Biopharma, Agile Therapeutics, Warner Chilcott,
Parke-Davis (now Pfizer). Katie currently serves on
the Board of Mayne Pharmaceuticals, an affiliate
faculty member of the Purdue University School of
Pharmacy and a Founding Member and Advisor to
IPhO.
Marcus brings more than 20 years’ experience
with listed companies. He possesses extensive
corporate finance experience, having led project
financing and capital rais ings in the industrial
sector. He has held senior managerial, tax and
finance roles with multi-national companies
including Lend Lease, Fortescue Metals and Rio
Tinto.
Investor Update – 17 September 2024
7
Meet Our
Management Team
John Clark
Chief Operating Officer
Dr Nicky Wallis
Chief Scientific Officer
Dr Herbert Brinkman
Head of Manufacturing
Dr Carol Worth
CMC Operations Manager
John has over 20 years of
pharmaceutical indus try
experien ce in phase I – IV clinical
trials across n umerous
therapeutic areas and mu ltiple
geographical regions . John has a
thorough knowledge o f ICH-GCP
and regulatory requirements and
held clinical operations
leadership roles responsible for
implementing global clinical
programs.
Nicky is a neuros cientis t and brings over
12 years of global expertise in clinical
developmen t, spanning pre-clinical
through to Phase 3 drug and device
developmen t. Her extensive experience
includes roles s uch as Clinical Trials
Program Specialis t at the Australian
Clinical Trials Alliance, Vice President of
Clinical Operations at Lateral P harma
Biotech, and Clinical Project Manager at
Orygen Youth Mental Health Research.
Herb has over 30 years of
experien ce in the pharmaceutical
indus try. He has prepared over 25
Chemistry Manufacturing and
Control sections and updates for
multiple filings for FDA and EU
regulatory agencies. Herb has filed
and commercially launched 9
products and contributed to filing 21
ANDAs for various s emi-solid and
parenteral products. He is also an
inventor on 14 patents.
Carol brings over 30 years of
indus try experience and a passion
for focusing on quality control and
quality assurance. She recently
served as Quality Manager at
Epichem Pty Ltd as Chief Technical
Officer at Suda Pharmaceuticals and
Solbec Pharmaceuticals. Carol has
also led product development
programs at Thermalife
International Pty Ltd/ Pharmasolv
Laboratories Pty Ltd.
Lidija Damjanovic
Head of Marketing and
Corporate Affairs
Paul Field
Business Development
Advisor
Lidija Damjanovic brings over 15
years of global experience and
passion for launching pharmaceutical
products and leading corporate
communications and affairs in the
biotech and pharmaceutical industry.
Her extensive leadership experience
in driving commercial growth
strategies includes marketing and
communications roles in companies
such as Merck Sharpe and Dohme,
Sartorius, Patheon and other global
organisations.
Paul brings over 30 years of
bus iness development experience
across a range of therapeutic
areas, including neurodegenerative
diseases, and he maintains a
deep network in the global
biopharmaceutical industry.
His experience includes bus iness
development roles at Cerecin,
Marinova, BioCurate and other
companies, and he serves on
the Boards of NASDAQ-listed 60
Degrees Pharmaceuticals and
Wintermute Biomed ical
Non Confidential Deck 18th October 2024
8
Meet Our
Scientific Advisory Board
Dr Sabrina Paganoni
Prof Leonard van den Berg
Dr Melanie Quintana
Dr Christian Freitag
Co-Director of the Neurological Clinical Research
Institute at the Massachusetts General Hospital,
Assistant Professor at Harvard Medical School, and
physician investigator at the Sean M. Healey and
AMG Center for ALS at Mass General. Dr Paganoni’s
research focuses on clinical trials and therapy
development for ALS. She has served as Principal
Investigator of several ALS clinical trials. She is the
co-Principal Investigator of the HEALEY ALS Platform
Trial, the world's firs t platform trial for ALS. She has
published over 100 peer-reviewed manuscripts and
received several awards, including the 2021 Top 10
Clinical Research Achievement Award. She co-ch airs
the Upper Motor N euron Tas k Force, the
Technology Committee, and the
Recruitment/ Retention/ Experience Committee at
NEALS.
Professor of Neurology who holds a Chair in
Experimental Neurology of motor neuron dis eas es at
the Univers ity Medical Center Utrecht in the
Netherlands. He als o is Director of the cen tre’s
Laboratory for Neuromuscular Dis eas e, Director of the
Netherlands ALS Center, Chairman of the
Neuromuscular Centre the N etherlands, and
Chairman of the European N etwork to Cure ALS
(ENCALS), a network of the European ALS Centres.
Prof. van den Berg did a fellowship in
neuroimmunology at the Neurological Institute at
Columbia University in New York and obtained his
PhD degree at UMC U trecht. He has been Professor of
Experimental Neurology since 2005 and leads a
research group focused on translational research into
ALS and other diseases of motor neurons .
Director and Senior Statistical Scientist at Berry
Consultants, where she specialises in designing
Bayesian adaptive clinical trials across a wide range
of therapeutic areas. Her work has included
numerous examples in designing platform trials ,
including the HEALEY ALS Platform Trial and clinical
trials in rare and progressive diseases, focusing on
developing disease progression models to design
better and more powerful clinical trials . Before
joining Berry Consultants , Melanie earned her P hD
in Statistics from Duke University and pursued a
Pos tdoc in Biostatistics at The University of
Southern California.
Over 20 years of experience in the pharmaceutical
indus try with positions in companies including
Hoffmann La Roche, Shire, and BTG, where he led
global clinical development projects . Dr. Freitag has
held the position of Chief Medical Officer at
Dynacure and Azafaros, where he was respons ible
for medical and regulatory strategy, including
clinical development of their lead compound in rare
diseases. Dr Freitag was the Medical Monitor on
Neurizon’s Phase 1 MEND study and oversaw
medical and clinical activities.
Mid-Year Update & Outlook December 2024
9
Phase 1
ALS MEND Study
The Phase 1 MEND Study was an open label, multicentre study involving 12 patients with ALS
with the goal of determining the recommended Phase 2/3 dose based on safety and preliminary efficacy
Study
Design
Gro up 2
6 Pat ients
Coh ort 2
4 mg/kg
Gro up 1
6 Pat ients
Coh ort 1
2 mg/kg
SMC
Con tin ue
Treatment
End of
Study
SMC
Coh ort 4
10 mg/kg
Con tin ue
Treatment
Coh ort 3
6 mg/kg
SMC
SMC
Study
Update
Open-Label E xtens ion Study
12-mon th s 10 mg/kg
Con tin ue
Treatment
Day 1
SMC Safety Monitoring Co mmit tee
Compassionate-use
Program
12 M onths
18 Months
30 Months
Treat ment Perio d
• Positive top-line data released in Q1 CY24
• 12 patients continued treatment with NUZ-001 under a compassionate-use program
• 10 patients have rolled-over into 12-month Open-Label Extension Study. Treatment continues to be very well-tolerated
• Updated ALSFRS-R and Survival Analysis to be generated by Berry Consultants.
• First group of 6 patients are entering their 27th month of continuous treatment with NUZ-001
• Phase 1 and baseline OLE data used to design pivotal registration adaptive Phase 2/3 Study, to commence in H2 CY24
Mid-Year Update & Outlook December 2024
10
Phase 1
ALS Open Label Extension Study
Compared to matched controls from the PRO-ACT Historical Database, treatment with NUZ-001 results in a significantly (X 2=10.35, p=0.00130)
longer survival of patients with ALS
Berry Consultants Statistical Analysis
Overall Survival Probability
∙ Berry’s a naly sis inv olved compa ring p atients in the PRO-AC T da tab ase with similar chara cteristics to
those in Neurizon’s Pha se 1 MEND Study ad justing for d iffering d iag nosis d urations
∙ Hazard ra tio of 0.237 ( 95% CI: (0.083,0.674), p = 0.007) ind icating that treatment with NUZ-001 reduces
the risk of d ea th by 76.3%
Analysis Method
Log-Rank Test
Dataset
Death Time
Imputation
Assumed
Cox Proportional Hazards Model
χ2
p-value
Hazard Ratio
95% C I
p-value
Leave out
10.35
0.00130
0.237
(0.083, 0.67 4)
0.007
Survival
Last Visit
11.47
0.0007 1
0.226
(0.080, 0.638)
0.005
Confirmed
Leave out
14.87
0.00012
0.210
(0.077, 0.576)
0.0024
Survival
Last Visit
16.77
0.00004
0.196
(0.072, 0.537)
0.0015
The PRO-AC T database is the largest publicly available repository of
merged ALS clinical study d ata . Data were pooled from 16
comp leted Pha se 2/3 ALS clinica l studies a nd one observ ational
stud y. O ver 8 million de-id entified longitudina lly collected da ta
points from more than 8,600 persons with A LS, including
demographics, family histories, a nd longitudinal clinical a nd
la boratory data.
1
Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features.
Mid-Year Update & Outlook December 2024
Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.
11
NUZ-001 selected for entry into the
HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial is a competitive process led by a group of expert ALS scientists
and members of the Healey & AMG Center Science Advisory Committee
Innovative Trial Structure
HEALEY ALS Platform Trial Design1
FDA a pproved Master Protocol
Active
Active
Design
• Shared master protocol
Placebo
• >70 clinical sites across the US
Active
Regimen A
Randomization
Active
Patient
Enro lls in
Platform Trial
Regimen B
Randomization
Randomization
• 3:1 active d rug to pla ceb o ratio
• 160-240 particip ants per reg imen
Active
• 5 regimens completed
Active
• 2 regimens enrolment closed
Placebo
Active
Active
Regimen C
Randomization
Active
Placebo
Shared infrastructure and
common protocol, allowing
sharing of p lacebo
participants
Placebo
• File US IND for NUZ-001 – December 2024
• File protocol a mend ment under MGH’s IND – Janua ry 2025
Placebo
• Neurizon to supply NUZ-001 – February 2025
Placebo
Sha red Placebo
Next Steps
• Study desig n p hase to create a regimen-specific protocol a mendment
completed
• Commence recruitment Q1 CY 2024
1.
HEALEY ALS Platform Trial (https://www.massgeneral.org/neurology/als/research/platform-trial).
Mid-Year Update & Outlook December 2024
12
Comparisons of ALSFRS-R Rates of Declines Across Studies
Favourable comparisons to the completed regimens in the HEALEY ALS Platform Trial and PRO-ACT Database 1
Rate of Decline in ALSFRS-R (points/month +/- SEM)
-1.8
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
NUZ-001 Phase 1
NUZ-001 Cohort 1
NUZ-001 Cohort 2
PRO-ACT Controls P1
Phase 1 MEND Study2
PRO-ACT Cohort 1
PRO-ACT Cohort 2
OLE
Regimen A
Regimen B
Regimen C
Regimen D
HEALEY ALS Platform Trial3
Regimen E
All Regimens
PRO-ACT Controls
1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive
features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC423 9834.
2. PharmAust Data on file.
3. Melanie Quintana, Eric Macklin*, Lori Chibnik, Joseph Marion, Anna McGlothlin, Michelle Detry, Matteo Vestrucci, Giorgio Paul on, Jeremy Shefner, Jinsy Andrews, James D. Berry,
Marianne Chase, Hong Yu, Alexander Sherman, Sabrina Paganoni, Merit Cudkowicz, for the HEALEY ALS Platform Trial Study Group. Statistical Innovation and Complexities in the
HEALEY ALS Platform Trial: Lessons Learned From the First Set of Regimens. Poster Presentation. ENCALS meeting 2024 Stockholm, Sweden June 17-20 2024.
Mid-Year Update & Outlook December 2024
13
Pre-Clinical Studies
MoA studies are ongoing,
employing gold standard
in vitro models of MND
Based on NUZ-001’s
activity through mTOR
inhibition, we are
assessing its efficacy in
other neurodegenerative
diseases with similar
underlying
pathophysiology
Our current areas of focus
include Alzheimer's
Disease (AD), Parkinson's
Disease (PD), and
Huntington's Disease (HD)
We are employing a suite
of in vitro models of
disease to assess its
efficacy
Mid-Year Update & Outlook December 2024
14
Pre-Clinical Data
HTRF TDP-43 Aggregation Assay
DMSO 0.1%
MG-132 0.1 μM
NUZ-001 0.625 μM
NUZ-001 1.25 μM
NUZ-001 2.5 μM
NUZ-001 Sulfone 0.625 μM
NUZ-001 Sulfone 1.25 μM
NUZ-001 Sulfone 2.5 μM
Rapamycin 0.625 μM
Rapamycin 1.25 μM
Rapamycin 2.5 μM
Dose-dependent effect of treatment was observed on TDP-43 aggregate reduction for:
• NUZ-001 at 0.625 μM (statistically significant; ~ 50% reduction) and 1.25 μM (~25% reduction)
• NUZ-001 Sulfone at 1.25 μM (statistically significant; ~ 55% reduction) and 2.5 μM (~ 25% reduction)
• Rapamycin at 3 μM (20% reduction)
Mid-Year Update & Outlook December 2024
15
Pre-Clinical Data
Multi-electrode Assay Activity
Number of Bursts
Number of Network Bursts
Inter-Burst Interval
DMSO 0.1%
Wild Type MN
WT
Level
NUZ-001 0.625 μM
WT
Level
NUZ-001 1.25 μM
NUZ-001 2.5 μM
NUZ-001 Sulfone 0.625
μM
WT
Level
NUZ-001 Sulfone 1.25 μM
NUZ-001 Sulfone 2.5 μM
NUZ-001 and NUZ-001 Sulfone significantly improved the ALS TDP-43 M337V associated phenotype/MEA activity by
increasing bursting (NUZ-001 0.625 µM p=<0.05), decreasing inter-burst interval, and increasing network burst activity
(NUZ-001 0.625 µM p=<0.005; NUZ-001 2.5 µM p=<0.00005 and NUZ-001 Sulfone 2.5 µM p=<0.00005) at day 18
(corresponding to 4 days of treatment with compound).
Mid-Year Update & Outlook December 2024
16
Strategic Partnerships
Realising Our Potential
Phase 1
Preclinical
US$122 Million
ex-US License
US$612 Million
License
March 2024
June 2024
Phase 1
Preclinical
US$3 Billion
License
US$480 Million
License
December 2024
December 2024
Mid-Year Update & Outlook December 2024
17
Chemistry, Manufacturing and Control
Manufacturing partners
• API - Syngene International
• Drug Product - Catalent Pharma
Solutions,
Both global leaders in the
manufacture and commercial supply
of pharmaceutical products.
Syngene is tasked with producing 60
kgs of GMP NUZ-001, which includes
an engineering batch of 15 kg and
three process validation batches of
15 kg each. These batches are
intended to validate the GMP
manufacturing process, aid in
product registration, and prepare
Neurizon for commercial supply.
Catalent Pharma Solutions
will handle the GMP production of
three registration batches,
amounting to over 500,000 tablets.
These batches will support product
registration and facilitate
commercial scale-up activities. The
manufactured product will be
utilized in the forthcoming adaptive
Phase 2/3 trial.
Current Inventory
• ~100,000 Placebo Tablets
• ~80,000 NUZ-001 Tablets
Mid-Year Update & Outlook December 2024
18
NUZ-001 Liquid Formulation
• Development of oral liquid
formulation of NUZ-001
is in progress
• New formulation development
initiated to address
administration challenges
encountered by subjects that
develop swallowing difficulties
with late-stage ALS
• New formulation planned
to be incorporated into
an amended Phase 1 Open Label
Extension Study or a Standalone PK comparison study in
CY25
Mid-Year Update & Outlook December 2024
19
NUZ-001 Regulatory Milestones
✓ Pre-IND Meeting
✓ Orphan Drug Designation
(7 years market exclusivity)
• IND Submission
• Fast Track Designation
✓ Pre-Submission Meeting
✓ Positive Opinion OMPD
✓ Formal OMPD Grant (10
years market exclusivity)
• Scientific Advice
✓ Pre-submission Meeting
• ODD
• Provisional Determination
• Provision Approval
Mid-Year Update & Outlook December 2024
20
Strategic Partnerships & Community Engagement
Mass General
Partnership with t he HEALEY ALS Plat form Trial enables
the effici ent evaluation of NUZ-001’s safety and efficacy In
Phase 2/3, within a patient-centric framework designed to
accelerate the path to market for NUZ-001.
MND Australia
Berry Consultants
Working t ogether to adv ance MND
treatments, advocacy, and awareness.
Partnership i n innov ativ e cl inical trial design, analysis,
execution, and software solutions for the clinical
devel opment of rare diseases.
Ncardia
Partnership i n drug discovery to accelerat e
devel opment processes t hrough the
integration of human iPSC technologies.
GenieUs
Partnership i n lev eragi ng cutting-edge
genomi c profiling in NUZ-001 Phase 1 Trial.
Fight MND
Connecting Science,
Expertise and Patient
Communities
Fi nding effective treatments and ultimatel y a
cure for Mot or Neurone Disease.
To advance NUZ-001 ALS therapy
to market and provide access,
support, and a horizon of hope
for patients with ALS and their
families.
I AM ALS
Forming part nership to expand awareness of
ALS, support pat ient communit ies with
resources and advocating for patient access to
ALS therapies.
Catalent
Syngene
Partnership i n Fill & Fi ni sh services for NUZ-001.
~100,000 Placebo Tablets
~80,000 NUZ-001 Tablets
Partnership i n manufacturing and securing
consist ent and sustainable supply of NUZ-001.
Mid-Year Update & Outlook December 2024
21
Patent Portfolio
•
•
6 patent families
Portfolio of 62 granted patents with 8
patent applications under examination
•
Covers key jurisdictions
(United States, Canada, Europe
(validated in 11 countries), Australia,
New Zealand, Japan, Korea, China, and
Hong Kong)
•
Broad protection over the method of
use of NUZ-001, and related
compounds for mTOR pathway-related
diseases
•
Covers neurodegenerative diseases
specifically Amyotrophic Lateral
Sclerosis, Alzheimer’s Disease,
Parkinson’s Disease & Huntington’s
Disease
•
Key patent granted in the US
(US 9,790,176) for “Compounds
For The Treatment of mTOR Pathway
Rel
Share your feedback
Discover